Rituximab biosimilar - Oncobiologics

Drug Profile

Rituximab biosimilar - Oncobiologics

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Oncobiologics
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Non-Hodgkin's lymphoma

Highest Development Phases

  • No development reported Non-Hodgkin's lymphoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in USA (IV, Infusion)
  • 07 Aug 2013 Rituximab biosimilar - Oncobiologics is available for licensing as of 07 Aug 2013. http://oncobiologics.com
  • 25 Feb 2013 Rituximab biosimilar licensed to Viropro in over 70 emerging markets, exclusively including Malaysia (& excluding China)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top